Research Analysts Set Expectations for SANA Q1 Earnings

Sana Biotechnology, Inc. (NASDAQ:SANA) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Sana Biotechnology in a research note issued to investors on Tuesday, March 18th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.24) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at ($0.59) EPS.

Other equities research analysts have also issued reports about the company. Citizens Jmp upgraded Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Tuesday. Jefferies Financial Group assumed coverage on Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7.00 target price on the stock. Finally, TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Sana Biotechnology Trading Down 3.4 %

NASDAQ SANA opened at $2.26 on Thursday. Sana Biotechnology has a 1-year low of $1.52 and a 1-year high of $10.50. The company has a 50 day moving average of $2.98 and a 200-day moving average of $3.19. The firm has a market cap of $504.59 million, a price-to-earnings ratio of -1.61 and a beta of 1.63.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02.

Insider Transactions at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Sana Biotechnology by 10.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,282 shares of the company’s stock valued at $455,000 after buying an additional 25,383 shares during the period. Vident Advisory LLC grew its stake in shares of Sana Biotechnology by 42.3% in the 4th quarter. Vident Advisory LLC now owns 43,291 shares of the company’s stock valued at $71,000 after buying an additional 12,861 shares during the period. Squarepoint Ops LLC raised its stake in Sana Biotechnology by 45.3% during the 4th quarter. Squarepoint Ops LLC now owns 178,431 shares of the company’s stock worth $291,000 after buying an additional 55,625 shares during the period. Two Sigma Advisers LP grew its stake in Sana Biotechnology by 677.0% in the fourth quarter. Two Sigma Advisers LP now owns 209,000 shares of the company’s stock valued at $341,000 after acquiring an additional 182,100 shares during the period. Finally, Two Sigma Investments LP increased its holdings in shares of Sana Biotechnology by 228.4% during the fourth quarter. Two Sigma Investments LP now owns 480,298 shares of the company’s stock valued at $783,000 after acquiring an additional 334,042 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.